{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-057684","form_type":"8-K","ticker":"LUDG","cik":"0001960262","company_name":"LUDWIG ENTERPRISES, INC.","filed_at":"2025-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.577340+00:00","generated_at":"2026-05-18T21:27:03.699691+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Ludwig Enterprises appoints Garth Lees-Rolfe as independent director","bullets":["Garth Lees-Rolfe appointed independent director effective June 23, 2025.","Over 19 years of finance/accounting experience; currently CFO of ABLi Therapeutics.","Previously CFO of Inhibikase Therapeutics (NASDAQ: IKT) and VP Finance at F-Star (NASDAQ: FSTX).","Spent 16 years at Ernst & Young, most recently as Senior Manager; holds CPA and Chartered Accountant licenses.","No family relationships with existing directors or executive officers."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-057684","json":"https://secwatch.observer/filing/0001213900-25-057684.json","markdown":"https://secwatch.observer/filing/0001213900-25-057684.md","text":"https://secwatch.observer/filing/0001213900-25-057684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1960262/000121390025057684/0001213900-25-057684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1960262/000121390025057684/ea0246925-8k_ludwig.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T21:27:03.699691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1643e0949b","claim":"Garth Lees-Rolfe was appointed as Independent Director at LUDWIG ENTERPRISES, INC..","evidence_excerpt":"On June 23, 2025, the Board appointed a new independent director, Garth Lees-Rolfe, to hold office until the earlier of the expiration of the term of office, a successor is duly elected and qualified, or the earlier of her death, resignation, disqualification, or removal.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1960262/000121390025057684/0001213900-25-057684-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Independent Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}